Vedolizumab (Entyvio) in Crohn's disease
Vedolizumab is a biological medicine (biologic), marketed under the brand name Entyvio (Takeda), used to treat moderate-to-severe inflammatory bowel disease (IBD). This clinical review focuses primarily on the onset speed of vedolizumab in Crohn's disease. It consolidates research on the use of vedolizumab in IBD, including how the introduction of a formulation for subcutaneous injection has challenged IBD services to review the use of vedolizumab in Crohn's disease. It presents up-to-date information that addresses misconceptions among health professionals and patients that vedolizumab is slow to work in Crohn's disease. It explores why specialist IBD nurses might raise the availability of different biologics during patient consultations, as well as how to hold quality conversations on the topic and address potential patient misconceptions.